Get the Stockscreener App
71.50
0.20%
-0.14
After Hours:
72.93
1.43
+2.00%
Ionis Pharmaceuticals Inc stock is traded at $71.50, with a volume of 1.47M.
It is down -0.20% in the last 24 hours and up +16.53% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$71.64
Open:
$71.23
24h Volume:
1.47M
Relative Volume:
0.60
Market Cap:
$11.40B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-23.52
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
-1.23%
1M Performance:
+16.53%
6M Performance:
+146.30%
1Y Performance:
+84.85%
1-Day Range:
$70.60
$71.98
1-Week Range:
$70.47
$74.42
52-Week Range:
$23.95
$74.42
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
71.50 | 11.42B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.90 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.74 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
814.17 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
313.54 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
What is the fair value estimate for Ionis Pharmaceuticals Inc. (ISI) stock in 20252025 Fundamental Recap & High Accuracy Investment Signals - newser.com
Published on: 2025-10-21 21:59:51 - newser.com
Can Ionis Pharmaceuticals Inc. (ISI) stock sustain revenue momentumBond Market & Real-Time Stock Entry Alerts - newser.com
Sector ETF performance correlation with Ionis Pharmaceuticals Inc.Portfolio Risk Summary & Technical Pattern Based Buy Signals - newser.com
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society - Business Wire
Is Ionis Pharmaceuticals Inc. stock poised for growth2025 Price Momentum & Weekly Hot Stock Watchlists - newser.com
Published on: 2025-10-21 01:16:00 - newser.com
Ionis Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Can Ionis Pharmaceuticals Inc. stock resist market sell offsNew Guidance & Community Trade Idea Sharing - newser.com
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares - The Motley Fool
News impact scoring models applied to Ionis Pharmaceuticals Inc.July 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock resilient in recession scenariosIPO Watch & Verified Technical Signals - nchmf.gov.vn
Can you recover from losses in Ionis Pharmaceuticals Inc.Portfolio Return Report & Smart Allocation Stock Tips - newser.com
Is Ionis Pharmaceuticals Inc. stock ready for breakoutJuly 2025 Outlook & Consistent Profit Alerts - newser.com
Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidanceTrade Ideas & Verified Technical Signals - newser.com
Is Ionis Pharmaceuticals Inc. building a consolidation baseEarnings Performance Report & Weekly High Return Stock Forecasts - newser.com
Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockGold Moves & Safe Capital Allocation Plans - newser.com
What recovery options are there for Ionis Pharmaceuticals Inc.July 2025 Setups & Detailed Earnings Play Strategies - newser.com
Should Ionis Pharmaceuticals' (IONS) Raised Revenue Guidance and Strong Q2 Results Prompt Investor Action? - Sahm
Can Ionis Pharmaceuticals Inc. stock weather global recessionTrade Exit Summary & Technical Entry and Exit Tips - nchmf.gov.vn
Layoff Watch: Can Ionis Pharmaceuticals Inc. stock weather global recessionJuly 2025 PostEarnings & Stepwise Trade Signal Guides - nchmf.gov.vn
Will Ionis Pharmaceuticals Inc. stock sustain high P E ratiosRecession Risk & Advanced Swing Trade Entry Plans - nchmf.gov.vn
Bear Alert: Is Ionis Pharmaceuticals Inc. stock a top pick in earnings seasonQuarterly Trade Report & Smart Money Movement Tracker - nchmf.gov.vn
Hedge Fund and Insider Trading News: Scott Bessent, Paul Tudor Jones, Crispin Odey, Ken Griffin, Millennium Management, Ionis Pharmaceutical Inc (IONS), Chicago Atlantic Real Estate Finance Inc (REFI), and More - Insider Monkey
CapEx per share of Ionis Pharmaceuticals, Inc. – DUS:ISI - TradingView
Ionis Pharmaceuticals Insider Sold Shares Worth $1,723,987, According to a Recent SEC Filing - MarketScreener
Ionis Pharmaceuticals director Parshall sells $358,721 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP Birchler sells $1.72m in shares By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Ionis Pharm - GuruFocus
Ionis Pharma EVP Devers sells shares worth $530,636 By Investing.com - Investing.com Canada
Ionis Pharmaceuticals EVP research, Eric Swayze, sells $3901 in IONS stock - Investing.com Nigeria
Ionis Pharmaceuticals EVP Birchler sells $1.72m in shares - Investing.com
Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IO - GuruFocus
Ionis Pharmaceuticals Hits New 52-Week High of $72.15 - Markets Mojo
Ionis Pharmaceuticals Hits New 52-Week High of $73.92 - Markets Mojo
Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating - MarketScreener
Ionis to hold third quarter 2025 financial results webcast - FinancialContent
Lobbying Update: $140,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):